Valneva (NASDAQ:VALN) Shares Gap Down to $8.50

Valneva SE (NASDAQ:VALN)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $8.50, but opened at $8.15. Valneva shares last traded at $8.06, with a volume of 9,082 shares.

Analyst Upgrades and Downgrades

VALN has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $26.00 price objective on shares of Valneva in a report on Thursday, March 21st. Guggenheim decreased their price objective on Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a report on Friday, March 22nd.

Valneva Trading Down 3.1 %

The business’s fifty day simple moving average is $7.68 and its 200-day simple moving average is $9.65. The company has a current ratio of 1.65, a quick ratio of 1.37 and a debt-to-equity ratio of 1.04.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. The company had revenue of $45.12 million for the quarter, compared to the consensus estimate of $45.06 million. As a group, sell-side analysts expect that Valneva SE will post 0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

A number of large investors have recently modified their holdings of the company. Jane Street Group LLC lifted its stake in Valneva by 85.9% in the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after purchasing an additional 7,664 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Valneva during the 1st quarter valued at $858,000. Finally, UBS Group AG bought a new position in shares of Valneva in the second quarter worth $31,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.